Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.
Description
Omda Cytodose, an oncology medication management solution from Omda, employs clinically validated protocols along with patient-specific parameters to ensure safer and more effective treatments for individuals battling cancer. This innovative system enhances the quality of care provided to oncology patients by fostering a seamless and collaborative treatment process among healthcare professionals, including doctors, pharmacists, and nurses. Omda Cytodose is designed to support a comprehensive range of adult and pediatric cancers, accommodating various medical treatments such as chemotherapy, immunotherapy, hormone therapy, and additional supportive medications. Initially created by a team of clinicians at one of Norway's premier cancer centers and introduced in 2001, Omda Cytodose has gained widespread adoption across healthcare regions in the Nordic countries, leading to the fulfillment of millions of medication orders. With a robust 15-year history marked by stability, reliability, and safety, the system is meticulously configured with chemotherapy protocols that reflect both national and international guidelines. This ensures that patients receive the most up-to-date treatment options available, further enhancing their chances of successful outcomes.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Lunit
Country
United States
Website
www.lunit.io/en
Vendor Details
Company Name
Omda
Founded
1999
Country
Norway
Website
omda.com/solutions/medication-management/omda-cytodose/